Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 7/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12309250 | 0.85 | DYRK1A (0.39) | DYRK1AAHRMCHR1NAMPTTTK | |
| SCHEMBL2067022 | 0.85 | DYRK1A (0.50) | DYRK1AAHRNAMPTTTK | |
| SCHEMBL3342789 | 0.83 | PDE10A (0.39) | DYRK1AAHR | |
| SCHEMBL17229848 | 0.83 | AHR (0.37) | DYRK1AAHRMCHR1 | |
| SCHEMBL6620552 | 0.83 | KDM4E (0.42) | DYRK1AAHRMCHR1 | |
| SCHEMBL18806166 | 0.80 | AHR (0.33) | DYRK1AAHR | |
| SCHEMBL17229820 | 0.80 | KDM4E (0.38) | DYRK1A | |
| SCHEMBL2065644 | 0.80 | DRD2 (0.32) | DYRK1ANAMPT | |
| SCHEMBL17229829 | 0.79 | MCHR1 (0.38) | AHRMCHR1 | |
| SCHEMBL12891186 | 0.79 | PDE10A (0.43) | AHRMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-9771326-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20150299123-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2015-10-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299123-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | DYRK1A 3654/4885AHR 3171/4885MCHR1 682/4885 |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | DYRK1A 399/4885AHR 1508/4885MCHR1 2325/4885 |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | DYRK1A 1640/4885AHR 2343/4885MCHR1 982/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | DYRK1A 3492/4885AHR 4415/4885MCHR1 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.